A Main Performer May Come for Percutaneous Coronary Intervention With Atrial Fibrillation in Japanese Patients

Ken Kozuma, MD, PhD

Percutaneous coronary intervention (PCI) plays a leading role in the treatment of coronary artery disease (CAD). PCI always requires dual periprocedural antithrombotic agents (so-called DAPT [dual antiplatelet therapy]) to avoid coronary events such as stent thrombosis (ST) and myocardial infarction (MI). Historically, rates of ST while using aspirin and warfarin were around 3%, and DAPT decreased this to less than 1%. Therefore, the concept that anticoagulation is inappropriate for the prevention of ST was established among cardiologists at the time of coronary stent introduction. Recently, the risk of ST has been dramatically decreased with the use of newer generation drug-eluting stents. However, it is still common knowledge that ST and periprocedural MI mostly occur on the first day of PCI. In this regard, the rapid effect of antiplatelet agents is important to further improve the outcome of PCI. Prasugrel is a newer generation P2Y12 receptor antagonist that has faster metabolism after intake and lower inter-individual variability in platelet response than clopidogrel. Prasugrel was shown to reduce ischemic events but to increase bleeding complications in the TRITON TIMI-38 trial. Prudent dose adjustment has been performed for its introduction to the Japanese patients. Pivotal trials such as Prasfit ACS and Prasfit elective for Japanese approval demonstrated equivalent incidence of bleeding complications and lower incidence of periprocedural MI than with clopidogrel. A dose of 3.75 mg daily is

---

**Anti-thrombotic Regimen for AF-PCI**

![Diagram of anti-thrombotic regimen for AF-PCI](image)

**Figure.** Current strategy for AF-PCI regarding duration of triple therapy. A, aspirin; ACS, acute coronary syndrome; AF, atrial fibrillation; C, clopidogrel; CKD, chronic kidney disease; NSAIDs, nonsteroidal anti-inflammatory agents; OAC, oral anticoagulation; P, low-dose prasugrel; PCI, percutaneous coronary intervention.
almost one-third of global dose without any increase in either thrombotic or bleeding complications in a real-world registry. Therefore, a kind of evidence lag between foreign countries and Japan has occurred in the antithrombotic medical field, because no global trial includes a 3.75-mg dose of prasugrel.

Atrial fibrillation (AF) is one of the most common diseases in the cardiovascular field. It requires oral anticoagulant therapy (OAC) for the prevention of thromboembolism. The effect of DAPT for stroke prevention in AF patients was demonstrated to be lower than that of warfarin in a large randomized trial. Therefore, both antiplatelet and anticoagulation agents were thought to be necessary for AF patients undergoing PCI according to the guidelines of CAD and AF. Several randomized trials have demonstrated the mistake of combination strategy using aspirin, clopidogrel, and warfarin/DOAC, so-called “triple therapy”. The European guideline on DAPT in CAD changed the clopidogrel, and warfarin/DOAC, so-called “triple therapy”. Thus, the question remaining is whether we can use low-dose prasugrel for Japanese patients with AF-PCI. Because carriers of CYP2C19 reduced-function alleles have been shown to be associated with ST and cardiovascular events because of their poor metabolism of clopidogrel after PCI, there is a concern of thrombotic complications regarding the “skip aspirin” strategy, especially in East Asia. Outside Japan, a 10-mg dose of prasugrel has been categorized as a contraindication with concomitant use of OAC because of the high bleeding risk. In this issue of the Journal, Otsuki et al focus on low-dose prasugrel use after PCI using DES compared with clopidogrel as part of triple therapy. This is an important message for interventional cardiologists who hesitate to stop aspirin for fear of ST caused by reduced effect of clopidogrel monotherapy. As previously stated, there were no benefits and more bleeding complications with triple therapy as compared with dual therapy. The use of low-dose prasugrel is anticipated as the appropriate choice for dual therapy in Japan. However, prospective randomized clinical trials for off-label use are difficult to perform because of the different doses used in other countries, as previously described. Furthermore, a new law on clinical research has come into force in Japan. We need large amounts of accumulated observational data to overcome these difficulties for Japanese patients. Otsuki et al are describing a local but very important issue, and it is the beginning of the story.

Conflict of Interest
The author has received remuneration from Sanofi, Daiichi-Sankyo, Bayer, and Boehringer Ingelheim.

References